销售价格: | ¥ N/A |
商品编号: | AS-LUN-237-0630 |
软件语言: | 英文 |
器械分类: | II |
生产厂家: | Pulmonx Corporation |
公司网址: | https://pulmonx.com/ |
认证信息: | FDA |
系统要求: | Windows/Mac |
交付方式: | 下载安装 |
The vision of Pulmonx is to be a global leader in bronchoscopic treatment for emphysema. The Zephyr® Valve System has clinically-proven results, reliability, patient selection tools, and ease of use.
The Zephyr Endobronchial Valve was granted a “breakthrough medical status”20 by the FDA and is indicated for bronchoscopic treatment of patients with hyperinflation associated with severe emphysema in regions of the lung that have little to no collateral ventilation (CV). The Zephyr Valve is an implantable device used to occlude all airways feeding the hyperinflated lobe of a lung that is most diseased with emphysema.
Trapped air escapes through the Zephyr Valves until the lobe volume is reduced. The remaining lobes are then able to expand more fully and work more efficiently, reducing pressure on the diaphragm and improving overall lung function.
30 to 60-minute procedure
Typically, 3 to 5 valves placed to completely occlude the lobe
Can be removed or replaced if needed
3-night stay in the hospital
Complications of the Zephyr Endobronchial Valve treatment can include, but are not limited to, pneumothorax, worsening of COPD symptoms, hemoptysis, pneumonia,
Appropriate patient selection is critical to the success of Zephyr Valve treatment. Clinical trial data have helped define the successful patient profile.17
Prior to treatment, physicians perform a clinical workup, including lung function and hyperinflation testing. In addition, Pulmonx offers assessment tools that precisely identify patients who are most likely to benefit from Zephyr Valve treatment.
非常抱歉,您只有购买软件后才能查看完整软件教程!
版本号 | 软件大小 | 下载地址 |
---|
版本号 | 软件大小 | 下载地址 |
---|